Gilead Sciences Inc (GILD)

64.220
-0.300(-0.47%)
  • Volume:
    169
  • Bid/Ask:
    64.960/66.780
  • Day's Range:
    64.220 - 64.520
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

GILD Historical Data

Time Frame:
Daily
05/09/2022 - 03/10/2022
64.22064.52064.52064.2200.17K-0.46%
64.52064.52064.52064.520-2.18%
65.96064.22065.96064.2200.02K+0.53%
65.61064.95065.61064.7700.14K+1.03%
64.94064.76064.94064.760+0.65%
64.52065.00065.00064.520-0.43%
64.80064.23064.80064.2300.10K-1.94%
66.08065.21066.08065.210+2.18%
64.67065.57065.57064.670-0.46%
64.97065.74065.74064.970+0.19%
64.85064.82065.23064.3800.24K-0.34%
65.07065.54065.54065.0700.01K+0.29%
64.88064.51064.88064.5100.20K-2.04%
66.23066.65067.06065.6600.82K-2.49%
67.92064.40067.92064.400+3.90%
65.37064.87065.37064.870-0.59%
65.76064.39065.76064.390+1.67%
64.68063.98064.68063.9800.15K+1.35%
63.82064.46064.62063.8200.01K-1.05%
64.50064.39064.50064.390-0.59%
Highest: 67.920Lowest: 63.820Difference: 4.100Average: 65.169Change %: -1.017
  • Good job GILD. bullish move forward
    0
    • Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
      1
      • Up Again
        0
        • Time to load up before the big rise coming next week
          3
          • Classic pump n’ dump. What a shambles
            1
            • Will reach above 95
              5
              • when? hahah
                0
            • Good time to accumulate.
              1
              • Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
                2
                • High chance to be trading above 90, good long stock
                  4
                  • By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
                    3